MX2009000359A - Metodos paratratar y limitar trastornos fibroticos y queloides. - Google Patents

Metodos paratratar y limitar trastornos fibroticos y queloides.

Info

Publication number
MX2009000359A
MX2009000359A MX2009000359A MX2009000359A MX2009000359A MX 2009000359 A MX2009000359 A MX 2009000359A MX 2009000359 A MX2009000359 A MX 2009000359A MX 2009000359 A MX2009000359 A MX 2009000359A MX 2009000359 A MX2009000359 A MX 2009000359A
Authority
MX
Mexico
Prior art keywords
keloids
treating
fibrotic disorders
methods
limiting
Prior art date
Application number
MX2009000359A
Other languages
English (en)
Inventor
Luciana Biagini Lopes
Elizabeth J Furnish
Charles Robert Flynn
Padmini Komalavilas
Alyssa Panitch
Colleen M Brophy
Original Assignee
Univ Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Arizona filed Critical Univ Arizona
Publication of MX2009000359A publication Critical patent/MX2009000359A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona métodos para tratar y/o limitar trastornos fibróticos y/o tratar o limitar cicatrices seleccionadas del grupo formado por queloides y cicatrices hipertróficas que comprenden administrar a un individuo que lo necesita una cantidad eficaz para tratar y/o limitar cicatrices seleccionadas del grupo formado por queloides y cicatrices hipertróficas de un polipéptido que comprende un polipéptido relacionado con HSP20.
MX2009000359A 2006-07-12 2007-07-10 Metodos paratratar y limitar trastornos fibroticos y queloides. MX2009000359A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83027906P 2006-07-12 2006-07-12
US84904106P 2006-10-02 2006-10-02
PCT/US2007/073144 WO2008008772A2 (en) 2006-07-12 2007-07-10 Methods for treating and limiting fibrotic disorders and keloids

Publications (1)

Publication Number Publication Date
MX2009000359A true MX2009000359A (es) 2009-05-08

Family

ID=38924094

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009000359A MX2009000359A (es) 2006-07-12 2007-07-10 Metodos paratratar y limitar trastornos fibroticos y queloides.

Country Status (13)

Country Link
US (1) US20110028398A1 (es)
EP (1) EP2051727A4 (es)
JP (1) JP5048772B2 (es)
KR (1) KR101267217B1 (es)
AU (1) AU2007272578B2 (es)
BR (1) BRPI0714383A2 (es)
CA (1) CA2657263A1 (es)
CR (1) CR10552A (es)
DO (1) DOP2009000005A (es)
MX (1) MX2009000359A (es)
NZ (1) NZ574717A (es)
SG (1) SG173369A1 (es)
WO (1) WO2008008772A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2898230C (en) 2007-01-10 2018-04-24 Purdue Research Foundation Polypeptide inhibitors of hsp27 kinase and uses therefor
WO2009021137A2 (en) 2007-08-07 2009-02-12 Purdue Research Foundation Kinase inhibitors and uses thereof
WO2010027832A1 (en) * 2008-08-25 2010-03-11 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to ctgf
BRPI0922448A2 (pt) 2008-12-10 2021-02-17 Purdue Research Foundation inibidor com base em peptídeo penetrante celular de quinases
US9890195B2 (en) 2009-07-27 2018-02-13 Purdue Research Foundation MK2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
WO2013134177A1 (en) * 2012-03-05 2013-09-12 Capstone Therapeutics Corp. Methods and compositions for improving spinal surgery outcomes
US9452218B2 (en) 2012-03-09 2016-09-27 Purdue Research Foundation Compositions and methods for delivery of kinase inhibiting peptides
KR102166543B1 (ko) * 2014-06-02 2020-10-16 주식회사 젬백스앤카엘 켈로이드 억제용 조성물 및 그 억제 방법
WO2016014621A1 (en) * 2014-07-22 2016-01-28 The Regents Of The University Of California Endosomal escape domains for delivery of macromolecules into cells
KR101667900B1 (ko) * 2016-01-15 2016-10-21 테고사이언스 (주) 켈로이드성 피부 또는 켈로이드 흉터 진단용 바이오마커 단백질 및 이의 이용

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5280038A (en) * 1992-03-13 1994-01-18 Virginia Commonwealth University Histidine as a protective agent in cardiac surgery and myocardial ischemic syndrome
US5985635A (en) * 1996-11-15 1999-11-16 Incyte Pharmaceuticals, Inc. Nucleic acids encoding novel human serine/threonine protein kinases
US7556722B2 (en) * 1996-11-22 2009-07-07 Metzger Hubert F Electroplating apparatus
US6475490B1 (en) * 1998-10-19 2002-11-05 Fordham University Compositions and methods for promoting tissue repair using heat shock proteins
US6812205B2 (en) * 2000-03-15 2004-11-02 The Brigham & Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
US7135453B2 (en) * 2001-08-23 2006-11-14 Arizona Board Of Regents Reagents and methods for smooth muscle therapies
AU2003260668A1 (en) * 2002-04-01 2003-10-20 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Biological affinity based delivery systems
WO2004075914A1 (en) * 2003-02-21 2004-09-10 Arizona Board Of Regents Methods for promoting wound healing and/or reducing scar formation
WO2005037236A2 (en) * 2003-10-17 2005-04-28 Arizona Board Of Regents Novel heat shock protein 20-related polypeptides and uses therefor
JP2009033589A (ja) * 2007-07-30 2009-02-12 Ricoh Co Ltd 画像形成装置、プログラムおよび記録媒体

Also Published As

Publication number Publication date
SG173369A1 (en) 2011-08-29
WO2008008772A3 (en) 2008-10-16
AU2007272578B2 (en) 2012-11-08
US20110028398A1 (en) 2011-02-03
EP2051727A4 (en) 2012-03-14
BRPI0714383A2 (pt) 2013-04-30
KR20090023685A (ko) 2009-03-05
CR10552A (es) 2009-05-04
DOP2009000005A (es) 2009-04-30
JP2009543800A (ja) 2009-12-10
JP5048772B2 (ja) 2012-10-17
AU2007272578A1 (en) 2008-01-17
WO2008008772A2 (en) 2008-01-17
EP2051727A2 (en) 2009-04-29
NZ574717A (en) 2011-11-25
CA2657263A1 (en) 2008-01-17
KR101267217B1 (ko) 2013-05-31

Similar Documents

Publication Publication Date Title
MX2009000359A (es) Metodos paratratar y limitar trastornos fibroticos y queloides.
MX2010009722A (es) Procedimiento de tratamiento del dolor cronico.
MX2010009724A (es) Procedimientos de tratamiento del dolor inflamatorio-.
MX2011009751A (es) Tratamiento de enfermedades relacionadas con factor nuclear (eritroide derivado 2) tipo 2 (nrf2) por inhibicion del transcrito antisentido natural a nrf2.
MX2010007564A (es) Composiciones de limpieza y/o tratamiento.
EP2575884A4 (en) APPLICATIONS AND COMPOSITIONS FOR THE TREATMENT OF ACNE INVERSA
MY162903A (en) Methods of treatment of pancreatic cancer
IN2012DN03824A (es)
MX339820B (es) Compuestos oligonucleottidos designados para inhibir el transcrito antisentido natrual apra apolipoproteina-a1.
IN2012DN02018A (es)
WO2011090741A3 (en) TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63
EP2493464A4 (en) METHYLSULFONYLMETHANE (MSM) FOR THE TREATMENT OF DRUG-RESISTANT MICROORGANISMS
WO2011022606A3 (en) Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
MX350046B (es) Tratamientos para trastornos gastrointestinales.
EP2963116A3 (en) Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt 1
IL206563A (en) A preparation or drug containing a suspension of blood cells that contain asparaginase for use in the treatment of pancreatic cancer
WO2011103528A3 (en) Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
MX2011013577A (es) Composiciones y metodos para tratar esclerosis lateral amiotrofica.
WO2011082409A3 (en) Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8
MY153948A (en) Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
MX349886B (es) Moleculas de union anti-pseudomonas lectina pisum satinum (psl) y usos de las mismas.
WO2012047956A3 (en) Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
MX348941B (es) Medios y metodos para trata y/o prevenir el cancer dependiente del ligando natural de receptor de aril-hidrocarburo.
WO2011019815A3 (en) Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq)
MX2009005114A (es) Uso de los profarmacos gabapentina y pregabalina para tratar el tinnitus.

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration